Diopsys, Inc., the market leader in office-based visual electrophysiology, announces the launch of the next evolution in Electroretinography (ERG) and Visual Evoked Potential (VEP) technology with the release of ARGOS™. The Diopsys®ARGOS™ ERG and VEP Vision Testing System is a powerful device that provides eye care specialists with the same visual electrophysiology suite available in the Diopsys® NOVA cart system, but in a tabletop version.
The company is also announcing a national roll-out of its Full Field Electroretinography (ffERG) testing protocols, which will be available on both the ARGOS™ and NOVA systems. Previously only available in beta test sites, Diopsys® ffERG tests use a unique, handheld mini-Ganzfeld dome to stimulate retinal cells. The Diopsys® ffERG results may be used to indicate the level of functional loss on patients with maculopathies, and give eye care providers the ability to measure the affect of maculopathies on vision through the presence of cataracts. The goal is to help eye care providers better manage the patient and potential for IOL procedures.
Diopsys, Inc. will officially unveil the new ARGOS™ device and release its proprietary ffERG testing protocols during the upcoming American Academy of Ophthalmology (AAO) Meeting, being held November 13 – 17, 2015, in Las Vegas, Nevada.
“The launch of the Diopsys® ARGOS™ and the wider availability of Full Field Electroretinography testing demonstrates our commitment to being the leader in offering sophisticated yet versatile visual electrophysiology testing for the eye care professional,” said Joe Fontanetta, president and CEO of Diopsys. “ERG and VEP were typically reserved for laboratory and academic settings. With the Diopsys® NOVA system, and now ARGOS™, eye care specialists have the tools they need to perform objective, functional testing, which provides important information to help in early detection and better patient management.”
For more information, visit the Diopsys® ARGOS™ webpage.